Brief: Panbela Therapeutics Inc Says On Aug 19, Co Received A Letter From Nasdaq Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
25/08/2022 13:13
Aug 25 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA THERAPEUTICS INC- ON AUG 19, CO RECEIVED A LETTER
FROM
NASDAQ OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING
RULE OR STANDARD
* PANBELA THERAPEUTICS INC - CO HAS UNTIL OCTOBER 3, 2022 TO
SUBMIT TO NASDAQ A PLAN TO REGAIN COMPLIANCE
Source: [ID: https://bit.ly/3dZ3ra5]
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants